Case Report: Contrasting BCL2 Upregulation With Venetoclax in a Case of Refractory Lymphomatoid Papulosis and Progressive Chronic Lymphocytic Leukemia

Case Report: Contrasting BCL2 Upregulation With Venetoclax in a Case of Refractory Lymphomatoid Papulosis and Progressive Chronic Lymphocytic Leukemia

A 57-year-old man affected by high-risk progressive chronic lymphocytic leukemia (CLL), primary resistant to first-line chemoimmunotherapy, developed a type A lymphomatoid papulosis (LyP) during a second progression of CLL. The two blood tumor entities were clonally unrelated. LyP presented with a d...

Full description

Bibliographic Details
Main Authors: Valerio Guarente, Giovanni Martino, Erica Dorillo, Filomena De Falco, Chiara Rompietti, Daniele Sorcini, Mariangela Brogna, Valeria Cardinali, Stefano Ascani, Andrea Marra, Paolo Sportoletti
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-09-01
Series:Frontiers in Oncology
Subjects:
T-cell lymphoma
chronic lymphocytic leukemia
venetoclax (BCL2 inhibitor)
lymphomatoid papulosis (LyP)
lymphomatoid papulosis treatment
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2021.729106/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2021.729106/full

Similar Items